ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Ligand Pharmaceuticals Inc. Partner Retrophin Receives Orphan Drug Designation For Sparsentan

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis …

University of California, San Diego (UCSD) Extension And Partner To Engage, Educate, And Empower Local Scientists

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 9, 2015 /PRNewswire-iReach/ — UC San Diego (UCSD) Extension is partnering with the San Diego Biotechnology Network (SDBN) to provide custom life science courses based on direct feedback from local scientists. Project management training has been chosen as the…

TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced that results from a clinical…

San Diego biotech to pay $2M for grant fraud

January 8, 2015 – 4:40 pm | Edit Post

Ansun execs doctored timesheets on work for the National Institutes of Health.

San Diego biotech to pay $2M for grant fraud

January 8, 2015 – 4:40 pm | Edit Post

Ansun execs doctored timesheets on work for the National Institutes of Health.

The 7th Annual Biotech Showcase™ to Begin Next Week

January 8, 2015 – 2:19 pm | Edit Post
The 7th Annual Biotech Showcase™ to Begin Next Week

Top-Tier Investor Conference to Foster Collaboration Among Leading Life Sciences Executives

NEW YORK and SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ — The 7th Annual Biotech Showcase™ launches next week in San Francisco amid a torrent of good news about the biotech industry, as it has been reported this week that IPOs, M&As, venture investment and drug approvals all exceeded expectations in 2014.  

More than 2,000 delegates, including qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives, are registered for the Biotech Showcase, which will be held at the Parc 55 Wyndham San Francisco – Union Square from January 12 – 14, 2015.  The event will feature presentations by more than 200 of the most innovative small to mid-sized biotech, specialty pharmaceutical and molecular diagnostic companies, of which 70% are publicly traded.

Biotech Showcase will also feature business workshops and plenary sessions that will explore topics key to continued success and growth of the biotech industry, including:

  • The state of public and private financial markets
  • Therapeutic advances in key areas, such as cancer immunotherapy and Type 1 diabetes
  • How to manage the regulatory thicket of the FDA, SEC, CMS and other agencies
  • The 3rd Annual Edition of The Life Sciences Report 2015 Small-Cap Watchlist

Attendees are also welcome to register for the “Biotech Showcase pre-event: The tactics of closing funding deals,” to be held on Sunday, January 11. The workshop is designed for junior executives and is focused on strategic discussion for securing funding at all levels. Registration for the Biotech Showcase pre-event is separate from the main conference’s primary registration.

Biotech Showcase 2015 registration information is available online.

About Biotech Showcase 2015:
Biotech Showcase is an investor conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

Biotech Showcase is co-produced by Demy-Colton Life Sciences Advisors and EBD Group.

About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Demy-Colton has developed a number of high-value conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter.

Media Contact:
Jason Rando, Exec. Vice President & COO
Tiberend Strategic Advisors, Inc.
+1 212.375.2665
jrando@tiberend.com

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

For more information please visit www.ebdgroup.com. Contact:
Erin Righetti EBD Group
+1 760 930 0500
erighetti@ebdgroup.com

Logo – http://photos.prnewswire.com/prnh/20150108/167851LOGO

SOURCE Demy-Colton Life Science Advisors

West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

January 8, 2015 – 1:44 pm | Edit Post
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

What a week for life sciences news, and it’s not even over. Perhaps we’ll get a slight break as the healthcare and biopharma worlds get on airplanes and descend upon San Francisco…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

January 8, 2015 – 1:44 pm | Edit Post
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

What a week for life sciences news, and it’s not even over. Perhaps we’ll get a slight break as the healthcare and biopharma worlds get on airplanes and descend upon San Francisco…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

January 8, 2015 – 1:44 pm | Edit Post

What a week for life sciences news, and it’s not even over. Perhaps we’ll get a slight break as the healthcare and biopharma worlds get on airplanes and descend upon San Francisco…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

January 8, 2015 – 1:44 pm | Edit Post
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More

What a week for life sciences news, and it’s not even over. Perhaps we’ll get a slight break as the healthcare and biopharma worlds get on airplanes and descend upon San Francisco…

[[Click headline to continue reading.]]